Principal Financial Group
QNCX icon

Principal Financial Group’s Quince Therapeutics QNCX Stock Holding History

Principal Financial Group’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-51
Closed -$937K – 2607
2021
Q3 		$937K Buy
51
+17
+50% +$270K ﹤0.01% 2019
2021
Q2 		$361K Buy
34
+1
+3% +$8.38K ﹤0.01% 2295
2021
Q1 		$236K Buy
+33
New +$237K ﹤0.01% 2339
2020
Q4 		– Sell
-31
Closed -$310K – 2453
2020
Q3 		$310K Hold
31
– – ﹤0.01% 2122
2020
Q2 		$291K Buy
+31
New +$284K ﹤0.01% 2090

Other funds holding QNCX

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Principal Financial Group's QNCX Position: Q4 2021 in Review

Principal Financial Group sold out of Quince Therapeutics (QNCX) in Q4 2021, closing a stake of 51 shares — an estimated $937K sold.

Principal Financial Group first reported a position in QNCX in Q2 2020 and held it in 5 quarters. The position peaked at $937K in Q3 2021. 97 funds tracked by Wall St. Rank hold QNCX as of Q4 2021.

  • Principal Financial Group reported no remaining Quince Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Principal Financial Group sold 51 Quince Therapeutics shares in Q4 2021, an estimated $937K.
  • Principal Financial Group first reported a position in Quince Therapeutics in Q2 2020 and held it in 5 quarters.
  • Principal Financial Group's Quince Therapeutics position peaked at $937K in Q3 2021.
  • 97 funds tracked by Wall St. Rank held Quince Therapeutics as of Q4 2021.

Based on Principal Financial Group's 13F filing for Q4 2021, filed 9 Feb 2022.